Date: 7 February 2014
Copyright: n/a
Notes:
This man with immunocompromised with autoimmune disease developed bilateral invasive aspergillosis and a galactomannan antigen OD in BAL of 9.0. He was started on voriconazole and responded well. Some weeks later his face became erythematous and slightly uncomfortable. The photographs show the remarkable extent of his voriconazole photosensitivity with very little conjunctivitis or cheilitis (lip dryness). Monochromator testing to narrow band UVB, UVA and visible light and provocation testing was within normal limits. Voriconazole was stopped after 9 months of therapy and reduction of immunosuppression, with resolution of photosensitivity.
Images library
-
Title
Legend
-
Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.
, 
-
Laryngeal aspergillosis, probably related to inhaled corticosteroids.
, 
, 
, 
-
VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
- A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
- Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
- Activity against azole-resistant fungal species.
- Low propensity for P450 drug-drug interactions.
-
SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.
-
Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010
, 
, 
